Cat. No. | Product name | CAS No. |
DC47260 |
Zunsemetinib
Featured
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases. |
1640282-42-3 |
DC47263 |
Zapnometinib
Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC50 of 5.7 nM. Zapnometinib exhibits antiviral activity against influenza virus and antibacterial activities. |
303175-44-2 |
DC47347 |
RSK4-IN-1
RSK4-IN-1 is identified with potent RSK4 inhibitory activity with an IC50 value of 9.5 nM. |
|
DC47351 |
ASP2453
Featured
ASP2453 is a potent, selective and covalent KRAS G12C inhibitor. ASP2453 inhibits the Son of Sevenless (SOS)-mediated interaction between KRAS G12C and Raf with an IC50 value of 40 nM. |
2241719-73-1 |
DC47352 |
KRAS mutant protein inhibitor 1
KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor for potential treatment in cancer. |
2642305-16-4 |
DC47353 |
KRAS G12C inhibitor 18
KRAS G12C inhibitor 18 is a potent and orally active KRAS G12C inhibitor. Anti-tumor activities. |
2649788-45-2 |
DC47354 |
RTIL 13
RTIL 13 is a potent inhibitor of dynamin GTPase, with an IC50 of 2.3 µM for dynamin I GTPase. RTIL 13 also targets pleckstrin homology lipid binding domain. RTIL 13 can inhibit receptor-mediated and synaptic vesicle endocytosis, with IC50s of 9.3 μM and 7.1 μM, respectively. |
1009376-10-6 |
DC47355 |
RM-018
RM-018 is a potent, functionally distinct tricomplex KRASG12C active-state inhibitor. RM-018 retains the ability to bind and inhibit KRASG12C/Y96D and could overcome resistance. RM-018 binds specifically to the GTP-bound, active [“RAS(ON)”] state of KRASG12C. |
2641993-55-5 |
DC47411 |
Anti-inflammatory agent 7
Anti-inflammatory agent 7 inhibits proinflammatory cytokines by blocking the NF-κB/MAPK signaling pathway in LPS-treated RAW 264.7 cells as well as mice. |
|
DC47567 |
MNK1/2-IN-5
MNK1/2-IN-5 is a potent and selective MNK1/2 inhibitor as a therapeutic agent. |
1426928-20-2 |
DC47569 |
MLKL-IN-1
MLKL-IN-1 is a covalent MLKL inhibitor with a KD of 50 μM. |
|
DC47574 |
MEK4 inhibitor-1
MEK4 inhibitor-1 is a novel MEK4 inhibitor against pancreatic adenocarcinoma with an IC50 value of 61 nM. |
2570386-36-4 |
DC47575 |
MEK4 inhibitor-2
MEK4 inhibitor-2 is a novel MEK4 inhibitor against pancreatic adenocarcinoma with an IC50 value of 83 nM. |
|
DC47577 |
HPK1-IN-8
HPK1-IN-8 is an allosteric, inactive conformation-selective inhibitor of full-length HPK1. |
1214561-09-7 |
DC47589 |
JNK3 inhibitor-1
JNK3 inhibitor-1 is a potent and selective JNK3 inhibitor (IC50 = 0.005 μM). JNK3 inhibitor-1 is orally bioavailable and brain penetrant. |
2622877-97-6 |
DC58063 |
HG106
Featured
HG106 is a potent SLC7A11 inhibitor and enhances ROS generation, ER stress, and ultimately growth arrest specifically in KRAS-mutant lung adenocarcinoma (LUAD). |
928712-10-1 |
DC47890 |
TAK1-IN-3
TAK1-IN-3 is a potent ATP-competitive TAK1 inhibitor. |
494772-87-1 |
DC47985 |
GNE-9815
Featured
GNE-9815 is among the most highly kinase-selective RAF inhibitors targeting KRAS mutant cancers via combination treatment. |
2729996-45-4 |
DC48036 |
B-Raf IN 2
B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer. |
2649372-20-1 |
DC48353 |
Ganoderterpene A
Ganoderterpene A attenuates LPS-induced inflammation and apoptosis via suppressing MAPK and TLR-4/NF-κB pathways in BV-2 cells. |
2682180-85-2 |
DC48354 |
8-CPT-2Me-cAMP sodium
8-CPT-2Me-cAMP sodium is a selective activator of exchange proteins activated by cAMP (Epac), the cAMP sensitive guanine nucleotide exchange factors (GEFs) for the small GTPases Rap1 and Rap2. 8-CPT-2Me-cAMP sodium activates Epac1 (EC50 = 2.2 μM), but not PKA (EC50> 10 μM). 8-CPT-2Me-cAMP sodium stimulates Epac-mediated Ca2+ release in pancreatic β-cells in vitro. |
634207-53-7 |
DC48355 |
Garsorasib
Garsorasib is a potent inhibitor of KRAS G12C with an IC50 of 10 nM. Garsorasib has the potential for the research of various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (non-small cell lung cancer) (extracted from patent WO2020233592A1, compound 2). |
2559761-14-5 |